Provided by Tiger Fintech (Singapore) Pte. Ltd.

Innate Pharma SA

1.87
-0.0250-1.32%
Volume:52.58K
Turnover:98.47K
Market Cap:172.34M
PE:-2.96
High:1.94
Open:1.94
Low:1.84
Close:1.90
Loading ...

US Equity Futures Rise Pre-Bell as Wall Street Kicks Off Holiday-Shortened Trading Week

MT Newswires Live
·
18 Feb

Top Premarket Gainers

MT Newswires Live
·
18 Feb

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Business Wire
·
17 Feb

Innate Pharma SA (IPHYF) Gets a Hold from Kepler Capital

TIPRANKS
·
14 Feb

3 Promising Penny Stocks With Market Caps Under US$500M

Simply Wall St.
·
01 Feb

Sector Update: Health Care Stocks Mixed Premarket Monday

MT Newswires Live
·
27 Jan

Innate Pharma doses first patient in IPH4502 study

TIPRANKS
·
27 Jan

Innate Pharma Doses First Patient in Phase 1 Trial of Cancer Drug Candidate

MT Newswires Live
·
27 Jan

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Business Wire
·
27 Jan

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Business Wire
·
21 Jan

Citi Keeps Their Buy Rating on Innate Pharma (IPHA)

TIPRANKS
·
20 Jan

Innate Pharma Price Target Maintained With a $11.50/Share by HC Wainwright & Co.

Dow Jones
·
17 Jan

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Business Wire
·
16 Jan

Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth

MT Newswires Live
·
10 Jan

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Business Wire
·
10 Jan

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire
·
20 Dec 2024